🇺🇸 FDA
Patent

US 7815921

Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy

granted A61PA61P1/04A61P11/00

Quick answer

US patent 7815921 (Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy) held by Ludwig-Maximilians-Universitat Munchen expires Mon Oct 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ludwig-Maximilians-Universitat Munchen
Grant date
Tue Oct 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P1/04, A61P11/00, A61P31/04, A61P31/10